{"id":2751,"date":"2026-06-26T20:50:00","date_gmt":"2026-06-26T20:50:00","guid":{"rendered":"https:\/\/cielcharlotte.com\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\/"},"modified":"2026-06-26T20:50:00","modified_gmt":"2026-06-26T20:50:00","slug":"skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease","status":"publish","type":"post","link":"https:\/\/development.brstdev.com\/cielcharlotte\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\/","title":{"rendered":"SKYRIZI\u00ae (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease"},"content":{"rendered":"

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a new 55 mg pre-filled syringe to support weight-based dosing for those patients weighing less\u2026<\/p>\n

Read the full release \u2192<\/a><\/p>\n

News provided by PR Newswire.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a new 55 mg pre-filled syringe to support weight-based dosing for those patients weighing less\u2026<\/p>\n","protected":false},"author":14,"featured_media":2753,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-2751","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-art-community"],"yoast_head":"\nSKYRIZI\u00ae (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease - Ciel Charlotte<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SKYRIZI\u00ae (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease - Ciel Charlotte\" \/>\n<meta property=\"og:description\" content=\"SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a new 55 mg pre-filled syringe to support weight-based dosing for those patients weighing less\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/development.brstdev.com\/cielcharlotte\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Ciel Charlotte\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-26T20:50:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/default-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"384\" \/>\n\t<meta property=\"og:image:height\" content=\"253\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ethan Parker\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ethan Parker\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\\\/\"},\"author\":{\"name\":\"Ethan Parker\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/4c5e38434c81d2ebb9c5787b29251450\"},\"headline\":\"SKYRIZI\u00ae (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease\",\"datePublished\":\"2026-06-26T20:50:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\\\/\"},\"wordCount\":57,\"image\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease-ai.png\",\"articleSection\":[\"Art Community\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\\\/\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\\\/\",\"name\":\"SKYRIZI\u00ae (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease - Ciel Charlotte\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease-ai.png\",\"datePublished\":\"2026-06-26T20:50:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/4c5e38434c81d2ebb9c5787b29251450\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease-ai.png\",\"contentUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease-ai.png\",\"width\":1536,\"height\":1024,\"caption\":\"SKYRIZI\u00ae (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SKYRIZI\u00ae (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#website\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/\",\"name\":\"Ciel Charlotte\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/4c5e38434c81d2ebb9c5787b29251450\",\"name\":\"Ethan Parker\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ethan-parkar-96x96.jpeg\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ethan-parkar-96x96.jpeg\",\"contentUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ethan-parkar-96x96.jpeg\",\"caption\":\"Ethan Parker\"},\"description\":\"Ethan Parker covers stories about community life, personal well-being, local initiatives, lifestyle trends, and the people working to create stronger communities. His writing looks for the human element behind larger developments, focusing on practical ideas and meaningful stories. Ethan brings an approachable perspective to subjects involving everyday life, community participation, creativity, and social connection.\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/author\\\/ethan-parker\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SKYRIZI\u00ae (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease - Ciel Charlotte","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"SKYRIZI\u00ae (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease - Ciel Charlotte","og_description":"SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a new 55 mg pre-filled syringe to support weight-based dosing for those patients weighing less\u2026","og_url":"https:\/\/development.brstdev.com\/cielcharlotte\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\/","og_site_name":"Ciel Charlotte","article_published_time":"2026-06-26T20:50:00+00:00","og_image":[{"width":384,"height":253,"url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/default-image.jpg","type":"image\/jpeg"}],"author":"Ethan Parker","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ethan Parker"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\/#article","isPartOf":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\/"},"author":{"name":"Ethan Parker","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/4c5e38434c81d2ebb9c5787b29251450"},"headline":"SKYRIZI\u00ae (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease","datePublished":"2026-06-26T20:50:00+00:00","mainEntityOfPage":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\/"},"wordCount":57,"image":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease-ai.png","articleSection":["Art Community"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\/","url":"https:\/\/development.brstdev.com\/cielcharlotte\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\/","name":"SKYRIZI\u00ae (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease - Ciel Charlotte","isPartOf":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#website"},"primaryImageOfPage":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\/#primaryimage"},"image":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease-ai.png","datePublished":"2026-06-26T20:50:00+00:00","author":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/4c5e38434c81d2ebb9c5787b29251450"},"breadcrumb":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/development.brstdev.com\/cielcharlotte\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\/#primaryimage","url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease-ai.png","contentUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease-ai.png","width":1536,"height":1024,"caption":"SKYRIZI\u00ae (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease"},{"@type":"BreadcrumbList","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/development.brstdev.com\/cielcharlotte\/"},{"@type":"ListItem","position":2,"name":"SKYRIZI\u00ae (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease"}]},{"@type":"WebSite","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#website","url":"https:\/\/development.brstdev.com\/cielcharlotte\/","name":"Ciel Charlotte","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/development.brstdev.com\/cielcharlotte\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/4c5e38434c81d2ebb9c5787b29251450","name":"Ethan Parker","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/ethan-parkar-96x96.jpeg","url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/ethan-parkar-96x96.jpeg","contentUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/ethan-parkar-96x96.jpeg","caption":"Ethan Parker"},"description":"Ethan Parker covers stories about community life, personal well-being, local initiatives, lifestyle trends, and the people working to create stronger communities. His writing looks for the human element behind larger developments, focusing on practical ideas and meaningful stories. Ethan brings an approachable perspective to subjects involving everyday life, community participation, creativity, and social connection.","url":"https:\/\/development.brstdev.com\/cielcharlotte\/author\/ethan-parker\/"}]}},"_links":{"self":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/2751","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/comments?post=2751"}],"version-history":[{"count":0,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/2751\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/media\/2753"}],"wp:attachment":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/media?parent=2751"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/categories?post=2751"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/tags?post=2751"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}